| Budget Amount *help |
¥26,910,000 (Direct Cost: ¥20,700,000、Indirect Cost: ¥6,210,000)
Fiscal Year 2014: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2013: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2012: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
|
|---|
| Outline of Final Research Achievements |
In our efforts to develop a new bispecific monoclonal antibody drug against breast cancer, we attempted to generate a tandem single-chain variable fragment (taFv) targeting both the T-cell CD3 antigen and Ephrin receptor A10 (EphA10), which were previously identified as breast cancer novel biomarker proteins. We constructed the taFv (EphA10/CD3) expression vector that contain two single chain Fv (scFv) joined by linker. The taFv was expressed transiently and verified for identity by Western blot analysis. By flow cytometry analysis, each monomer and dimer bound both antigens EphA10 and CD3. The taFvs showed highly cytotoxicity specifically against EphA10 over-expression cancer cell line. Most notably, the cytotoxicity of taFv dimer was higher than taFv monomer at low Effector/Target ratio and low concentration. This taFv (EphA10/CD3) could induce EphA10 specific cytotoxicity. And also, this BsAb showed the therapeutic effects against EphA10-expressing tumor cells in vivo.
|
